Advaxis has taken its investors on a bit of a roller coaster ride this year.
The FDA slapped a clinical hold on a combo study of its lead drug axalimogene filolisbac and AstraZeneca’s Imfinzi in wake of a patient death, which resolved months later after a C-suite overhaul. Late Wednesday, the New Jersey biotech added to the drama by quietly disclosing that Amgen has dropped their $540 million immunotherapy pact.
First inked in 2016 with $65 million upfront, the deal centered around ADXS-NEO, which is designed to recruit a T cell attack on cancer using bioengineered bacteria. But Amgen is returning worldwide rights for development and commercialization just as Advaxis is enrolling patients for its proof-of-concept work — the last step before Amgen was supposed to take over.
The news sent shares $ADXS into a steep drop, plunging 28% in pre-market trading.
Without giving any reasons for the termination, Advaxis says it will now evaluate whether to re-partner the ADXS-NEO program. Neither companies have responded to my requests for comment.
Amgen $AMGN will have until February 8, 2019 to tie up any loose ends.
In 2017 and 2018 Advaxis has received $5.8 million and $7.5 million in reimbursements respectively for an alliance that once promised $475 million in milestones.
The biotech is also partnered with Bristol-Myers on an Opdivo combination program for axalimogene filolisbac.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription